糖尿病足由于全身情況的不同，傷口愈合較其他傷口困難，在TIME原則下進(jìn)行處理當(dāng)中，可以采取進(jìn)一步治療促進(jìn)傷口的愈合，如可以選擇更加高級(jí)的新型敷料，或進(jìn)行傷口負(fù)壓引流的治療。負(fù)壓治療在糖尿病足潰瘍的治療方面已經(jīng)被認(rèn)可，它可以減少細(xì)菌定植，減輕水腫，減少滲出，促進(jìn)傷口愈合，是不錯(cuò)的選擇方式，但是對(duì)于缺血足和感染過(guò)于嚴(yán)重的糖尿病足，這種治療也需要謹(jǐn)慎。在新型敷料的使用方面，還沒(méi)有更多的研究，此外因其價(jià)格昂貴，需要對(duì)其性價(jià)比進(jìn)行評(píng)估，具體可見表2-2。

表2-2　糖尿病足高級(jí)治療方法

（韓春茂　沈月宏）

參 考 文 獻(xiàn)

[1] Suzie Calne, Christine M, Madeleine F, et al. Wound bed preparation in practice. European Wound Management Association (EWMA). Position Document, 2004:1.

[2] Falanga V. FACP Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair Regen, 2000,8:347-352.

[3] Ligresti C, Bo F. Wound bed preparation of difficult wounds: an evolution of the principles of TIME. Int Wound J, 2007,4:21-29.

[4] 韓春茂．慢性傷口診療的指導(dǎo)意見(征求意見稿).

[5] Flanagan M. Wound measurement: can it help us to monitor progression to healing? J Wound Care, 2003,12(5):189-194.

[6] Moffatt CJ, Harper P. Leg Ulcers: Access to clinical education. New York:Churchill Livingstone, 1997.

[7] Westerhof W, van Ginkel CJ, Cohen EB, et al. Prospective randomised study comparing the debriding effect of krill enzymes and a non-enzymatic treatment in venous leg ulcers. Dermatologica, 1990, 181(4):293-297.

[8] Ug A, Ceylan O. Occurrence of resistance to antibiotics, metals, and plasmids in clinical strains of Staphylococcus spp. Arch Med Res, 2003,34(2):130-136.

[9] GEORGE D. WINTER. Formation of the scab and the rate of epithelization of superficial wounds in the skin of theyoung domestic pig. Nature 20 January, 1962, 193:293-294.

[10] Denis Okan BHSc, MD , Kevin Woo MSc, et al. The Role of Moisture Balance in Wound Healing. Advances in Skin & Wound Care, January2007,20(1):39-53.

[11] Liu Y, Min D, Bolton T, et al. Increased matrix metalloproteinase- predicts poor wound healing in diabetic foot ulcers. Diabetes Care, 2009 Jan, 32(1):117-119.

[12] Mi Q, Rivière B, Clermont G, et al. Agent-based model of inflammation and wound healing: insights into diabetic foot ulcer pathology and the role of transforming growth factor-beta1. Wound Repair Regen, 2007 Sep-Oct, 15(5):671-682.

[13] Galkowska H, Wojewodzka U, Olszewski WL. Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair Regen, 2006 Sep-Oct, 14(5):558-565.

[14] Jude EB, Blakytny R, Bulmer J, et al. Transforming growth factor-beta 1,2, 3 and receptor type I and II in diabetic foot ulcers. Diabet Med, 2002,19(6):440-447.

[15] Blakytny R, Jude EB, Martin Gibson J, et al. Lack of insulin-like growth factor-1 (IGF-1) in the basal keratinocyte layer of diabetic skin and diabetic foot ulcers. J Pathol, 2000,190(5):589-594.

[16] Jude EB, Blakytny R, Bulmer J, et al. Transforming growth factor-beta 1,2,3 and receptor type I and II in diabetic foot ulcers. Diabet Med, 2002 Jun, 19(6):440-447.

[17] Xinlei Hu, Huafeng Sun, Chunmao Han, et al. Topically applied rhGM-CSF for the wound healing: A systematic review. Burn, 2010.

[18] Banwell PE, Teot L. Topical negative pressure (TNP): the evolution of a novel wound therapy. J Wound Care, 2003,12(1):22-28.

[19] Redekop WK, McDonnell J, Verboom P, et al. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics, 2003,21(16):1171-1183.

[20] Edmonds ME, Foster AVM, McColgan M. Dermagraft: a new treatment for diabetic foot ulcers. Diabet Med, 1997,14:1010-1011.

[21] Veves A, Sheehan P, Pham HT. A randomised, controlled trial of Promogran (a collagen/oxidised regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg, 2002,137(7):822-827.

[22] King L. Impaired wound healing in patients with diabetes. Nurs Stand, 2001,15(38):39-45.

[23] Albertson S, Hummel RP, Breeden M, et al. PDGF and FGF reverse the healing impairment in protein-malnourished diabetic mice. Surgery, 1993,114(2):368-372.

[24] Suzie C,wound bed preparation in practice, 2004.11.